CorMedix (CRMD) Common Equity (2010 - 2025)

CorMedix has disclosed Common Equity across 16 years of filings, most recently posting $405.3 million for Q4 2025.

• Common Equity for Q4 2025 came in at $405.3 million, up 378.76% year-over-year; the trailing twelve-month figure through Dec 2025 was $405.3 million (up 378.76% YoY), and the FY2025 annual result was $405.3 million, up 378.76% from the prior year.
• Common Equity came in at $405.3 million for Q4 2025 at CorMedix, up from $374.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $405.3 million in Q4 2025 to a low of $46.2 million in Q2 2024.
• The 5-year median for Common Equity is $66.1 million (2021), against an average of $107.1 million.
• Across the five-year window, Common Equity soared 31764174.79% in 2021 and retreated 29.43% in 2024, its largest moves.
• CorMedix's Common Equity stood at $62.8 million in 2021, then decreased by 12.32% to $55.1 million in 2022, then climbed by 27.39% to $70.1 million in 2023, then gained by 20.69% to $84.7 million in 2024, then jumped by 378.76% to $405.3 million in 2025.
• The last three Common Equity figures came in at $405.3 million (Q4 2025), $374.1 million (Q3 2025), and $220.6 million (Q2 2025), per Business Quant data.